Crinetics Pharmaceuticals Inc.
Clinical trials sponsored by Crinetics Pharmaceuticals Inc., explained in plain language.
A biopharmaceutical company developing therapies for endocrine diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could tame hormone disorder Cushing's syndrome Results expected Oct 2026 (estimated)
- New pill may help adults with rare adrenal disorder cut back on steroids Results expected May 2027 (estimated)
- New targeted drug trial opens for patients with Hard-to-Treat neuroendocrine cancers Results expected Aug 2027 (estimated)
- New pill aims to tame flushing and diarrhea in rare cancer syndrome Results expected Aug 2027 (estimated)
-
New pill may help adults with rare adrenal disorder cut back on steroids
Disease control Recruiting nowThis study tests a new drug, atumelnant, in 150 adults with classic congenital adrenal hyperplasia (CAH). The goal is to see if it can safely control hormone levels and allow patients to take lower doses of their usual steroid medications. Participants will receive either atumeln…
Phase 3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill could help kids with rare hormone disorder cut back on steroids
Disease control Recruiting nowThis study tests a daily oral medication called atumelnant in children aged 1 to 18 with classic congenital adrenal hyperplasia, a genetic condition that disrupts hormone production. The goal is to see if the drug can safely normalize hormone levels and allow patients to lower th…
Phase 2/3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New targeted drug trial opens for patients with Hard-to-Treat neuroendocrine cancers
Disease control Recruiting nowThis study tests a new drug called CRN09682 in people with progressive metastatic neuroendocrine neoplasms and other solid tumors that have a specific marker (SST2). The trial has two phases: first, finding the safest dose, then testing that dose in more patients. About 150 parti…
Phase 1/2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New pill shows promise for rare hormone disorder in Long-Term trial
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a daily pill called atumelnant for people with classic congenital adrenal hyperplasia (CAH). The drug works by blocking a hormone receptor to help control excess androgen production. Researchers will monitor 150 part…
Phase 2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill aims to tame flushing and diarrhea in rare cancer syndrome
Symptom relief Recruiting nowThis Phase 3 trial tests whether the experimental drug paltusotine can reduce flushing and diarrhea in adults with carcinoid syndrome caused by neuroendocrine tumors. About 141 participants will receive either paltusotine or a placebo daily for 12 weeks. The study measures how mu…
Phase 3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC